Category Archives: Biologics/Biosimilars

This Shield of Patents Protects the World’s Best-Selling Drug

Over Humira’s lifetime, AbbVie has secured more than 100 patents to prevent anyone from attempting to copy the biologic, with $16 billion in annual sales. By Cynthia Koons Humira, a treatment for inflammatory diseases such as rheumatoid arthritis and psoriasis … Continue reading

Posted in Biologics/Biosimilars, Uncategorized | Leave a comment

Draft Pharmaceutical Policy, 2017

Source: All India Drug Action Network (AIDAN) The Department of Pharmaceuticals has circulated a Draft Pharmaceutical Policy, 2017 which can be accessed here. The draft policy identifies the following key objectives: a. Making essential drugs accessible at affordable prices to the … Continue reading

Posted in API, Biologics/Biosimilars, Evergreening, Innovation, IPR, Patent, R&D, Uncategorized | Leave a comment

No logic in extending length of patents

Granting a longer term for pharmaceutical patents will result in delays in the entry of generic versions and could adversely affect access to medicines   By Feroz Ali, Live Mint | July 28, 2017 A proposal to further extend the … Continue reading

Posted in Biologics/Biosimilars, Data Exclusivity, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS, TRIPS flexibilities, TRIPS plus, TRIPS&IP rights, Uncategorized | Leave a comment

Roche vs Indian Pharma: The battle for a cheaper cancer drug

By Divya Rajagopal, The Economic Times|May 14, 2017 Let’s hark back to the Nineties. The HIV-AIDS epidemic was spreading across Africa, leaving thousands dead, in spite of the existence of anti-retroviral drugs (ARVs). The cost of the treatment, around $10,000, … Continue reading

Posted in Biologics/Biosimilars, Campaign for Affordable Trastuzumab, Cancer, Uncategorized | Leave a comment

Competition Commission of India pulls up Roche for anti-competitive practices

By Jyotsna Singh, Scroll | April 27, 2017 In a landmark order, the commission has initiated an investigation into the multinational pharmaceutical company’s activities. The Competition Commission of India has initiated an investigation into Swiss pharmaceutical giant Roche for unfair … Continue reading

Posted in Biologics/Biosimilars, Campaign for Affordable Trastuzumab, Cancer, Uncategorized | Tagged , , , | Leave a comment

CCI to investigate Swiss drugmaker Roche over breast cancer biosimilar

By Divya Rajagopal, The Economic Times | April 26, 2017 MUMBAI: The Competition Commission of India (CCI) will investigate Swiss drugmaker Roche over alleged attempts to block competitors from selling breast cancer drug Trastuzumab. The investigation has to be completed … Continue reading

Posted in Biologics/Biosimilars, Campaign for Affordable Trastuzumab, Cancer, Uncategorized | Tagged , , , , | Leave a comment

Indian competition commission issues a path breaking order on abuse of dominant position in pharmaceuticals

Rules Roche’s practices prima facie appear to be aimed at blocking affordable biosimilar trastuzumab – a cancer drug – in India In July 2016, Mylan Pharmaceuticals and Biocon Limited approached the Competition Commission of India regarding Roche’s anti-competitive conduct to … Continue reading

Posted in Anti competition, Biologics/Biosimilars, Campaign for Affordable Trastuzumab, Cancer | Tagged , , , , , | Leave a comment